Journal
ATHEROSCLEROSIS
Volume 287, Issue -, Pages 81-88Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2019.06.897
Keywords
Inflammation; Macrophage; Thrombin inhibitor; Atherosclerosis; Obesity
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
Background and aims: The non-vitamin K oral anticoagulant dabigatran etexilate (dabigatran) is increasingly prescribed to patients with non-valvular atrial fibrillation and venous thromboembolism. Adipose tissue (AT) inflammation during obesity plays a crucial role in the development of insulin resistance, type II diabetes and atherogenesis. The aim of the present study was to investigate the effects of thrombin inhibition by dabigatran in a combined model of diet-induced obesity and atherosclerosis. Methods: Female Low density lipoprotein receptor knockout (Lldr(-/-)) mice were fed a high-fat diet containing 5 mg/g dabigatran or matching control for 20 weeks. Results: Dabigatran-treated animals showed increased adipocyte hypertrophy, but reduced numbers of pro-inflammatory M1-polarized macrophages in the adipose tissue. Abundance of pro-inflammatory M1 macrophages was also decreased in the aortic wall of dabigatran-fed mice. Multiple circulating cytokines were reduced, indicating an effect in systemically relevant secretory compartments such as the AT. Conclusions: Dabigatran treatment reduces pro-inflammatory M1 macrophages in atherosclerotic lesions, thereby contributing to plaque stabilizing and atheroprotective effects of the thrombin inhibitor. This finding is not restricted to the vascular wall but is also present in AT where dabigatran treatment reduced the release of pro-inflammatory cytokines and accumulation of M1 macrophages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available